GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 396 participants.

Also called NCT07617155

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 396 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07617155
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07617155. Randomized; quadruple masking; primary purpose prevention. Start 2026-09 (anticipated); primary completion 2028-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
Acronym
RECAP-GLP1
Condition
Hypertriglyceridemia Induced Acute Pancreatitis
Condition
Recurrent Acute Pancreatitis
Condition
Pancreatitis Relapsing
Condition
Hypertriglyceridemia
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo (Normal Saline)
Lead sponsor
Peking Union Medical College Hospital (class: other)

Record details

Record id
cardio:ct-nct07617155
Content hash
cfb0db86195a467855e1fb8d21608dffeb9a7028269af12a65ab1728d0a43c81